{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:53:17Z","timestamp":1772121197500,"version":"3.50.1"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"del Instituto de Salud Carlos III, Ministerio de Econom\u00eda y Competitividad, Red Tem\u00e1tica de Investigaci\u00f3n Cooperativa en C\u00e1ncer"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.leukres.2016.08.004","type":"journal-article","created":{"date-parts":[[2016,8,11]],"date-time":"2016-08-11T06:58:02Z","timestamp":1470898682000},"page":"38-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["New drugs for follicular lymphoma"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0587-591X","authenticated-orcid":false,"given":"Marc","family":"Sorigue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep-Maria","family":"Ribera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Motll\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan-Manuel","family":"Sancho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2016.08.004_bib0005","series-title":"WHO Classification of Tumours of Haemapoietic and Lymphoid Tissues","year":"2008"},{"key":"10.1016\/j.leukres.2016.08.004_bib0010","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1200\/JCO.2012.45.0866","article-title":"R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi","volume":"31","author":"Federico","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"S3","key":"10.1016\/j.leukres.2016.08.004_bib0015","doi-asserted-by":"crossref","first-page":"iii76","DOI":"10.1093\/annonc\/mdu200","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Dreyling","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.leukres.2016.08.004_bib0020","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood-2013-03-491514","article-title":"Improvements in observed and relative survival in follicular grade 1\u20132 lymphoma during 4 decades: the Stanford University experience","volume":"122","author":"Tan","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.08.004_bib0025","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.08.004_bib0030","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/annonc\/mds429","article-title":"Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices","volume":"24","author":"Nooka","year":"2013","journal-title":"Ann. Oncol."},{"issue":"Suppl. (3)","key":"10.1016\/j.leukres.2016.08.004_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10428194.2011.629897","article-title":"Clinical practice guidelines for first-line\/after-relapse treatment of patients with follicular lymphoma","volume":"52","author":"L\u00f3pez-Guillermo","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2016.08.004_bib0040","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1365-2141.2011.08969.x","article-title":"Guidelines on the investigation and management of follicular lymphoma","volume":"156","author":"McNamara","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2016.08.004_bib0045","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.radonc.2011.05.013","article-title":"Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial","volume":"100","author":"Lowry","year":"2011","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.leukres.2016.08.004_bib0050","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.leukres.2015.05.009","article-title":"The long term follow-up of early stage follicular lymphoma treated with radiotherapy, chemotherapy or combined modality treatment","volume":"39","author":"Sancho","year":"2015","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2016.08.004_bib0055","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2016.08.004_bib0060","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.08.004_bib0065","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1158\/1535-7163.MCT-12-1182","article-title":"Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models","volume":"12","author":"Herter","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.leukres.2016.08.004_bib0070","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1182\/blood-2011-09-378323","article-title":"Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study","volume":"119","author":"Czuczman","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.08.004_bib0075","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1182\/blood.V126.23.2741.2741","article-title":"Trial of ofatumumab (OFA) in previously untreated follicular non-Hodgkin lymphoma (NHL): CALGB 50901 (Alliance)","volume":"126","author":"Rosenbaum","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.08.004_bib0080","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1365-2141.2012.09086.x","article-title":"Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma","volume":"157","author":"Czuczman","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2016.08.004_bib0085","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1200\/JCO.2012.46.9718","article-title":"Obinutuzumab (GA101) in patients with relapsed\/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study","volume":"31","author":"Salles","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2016.08.004_bib0090","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1200\/JCO.2014.59.2139","article-title":"Trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-Cell non-Hodgkin lymphoma: final analysis of the GAUSS study","volume":"33","author":"Sehn","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2016.08.004_bib0095","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1182\/blood-2013-01-481341","article-title":"Obinutuzumab (GA101) plus CHOP or FC in relapsed\/refractory follicular lymphoma: results of the GAUDI study (BO21000)","volume":"122","author":"Radford","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.08.004_bib0100","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2014.59.2139","article-title":"GADOLIN: primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma","author":"Sehn","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2016.08.004_bib0105","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(16)30097-3","article-title":"Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial","author":"Sehn","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2016.08.004_bib0110","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/annonc\/mdm114","article-title":"A phase I\/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma","volume":"18","author":"Leonard","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.leukres.2016.08.004_bib0115","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1093\/annonc\/mdr620","article-title":"Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness","volume":"23","author":"Czuczman","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.leukres.2016.08.004_bib0120","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1002\/cncr.23890","article-title":"Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma","volume":"113","author":"Leonard","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2016.08.004_bib0125","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1002\/cncr.28299","article-title":"A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701","volume":"119","author":"Grant","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2016.08.004_bib0130","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1182\/blood.V122.21.1810.1810","article-title":"Safety profile and clinical response to MEDI-551, a humanized monoclonal anti-CD19, in a phase 1\/2 study In adults with relapsed or refractory advanced B-cell malignancies","volume":"122","author":"Forero-Torres","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.08.004_bib0135","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1182\/blood.V126.23.1528.1528","article-title":"Phase IIa study of single-agent MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma","volume":"126","author":"Jurczak","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.08.004_bib0140","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1200\/JCO.2012.42.7211","article-title":"Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I\/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab","volume":"31","author":"Fayad","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2016.08.004_bib0145","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.14094","article-title":"A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy","author":"Goy","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2016.08.004_bib0150","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","author":"Kantarjian","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2016.08.004_bib0155","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S1470-2045(15)70128-2","article-title":"Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study","volume":"16","author":"Palanca-Wessels","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2016.08.004_bib0160","doi-asserted-by":"crossref","first-page":"8503","DOI":"10.1200\/jco.2015.33.15_suppl.8503","article-title":"Two doses of polatuzumab vedotin (anti-CD79b antibody-drug conjugate) in patients with relapsed\/refractory follicular lymphoma: durable responses at lower dose level","volume":"33","author":"Advani","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2016.08.004_bib0165","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1200\/JCO.2014.59.5363","article-title":"Mechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma","volume":"33","author":"Gribben","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2016.08.004_bib0170","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1200\/JCO.2008.21.1169","article-title":"Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's lymphoma","volume":"27","author":"Witzig","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2016.08.004_bib0175","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/cncr.28405","article-title":"Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas","volume":"120","author":"Ahmadi","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2016.08.004_bib0180","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/bjh.12755","article-title":"Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma","volume":"165","author":"Tuscano","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2016.08.004_bib0185","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1200\/JCO.2014.59.9258","article-title":"Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance)","volume":"33","author":"Leonard","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2016.08.004_bib0190","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1182\/blood.V124.21.799.799","article-title":"Rituximab plus lenalidomide improves the complete remission rate in comparison with rituximab monotherapy in untreated follicular lymphoma patients in need of therapy. Primary endpoint analysis of the randomized phase-2 trial SAKK 35\/10","volume":"124","author":"Kimby","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.08.004_bib0195","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S1470-2045(14)70455-3","article-title":"Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial","volume":"15","author":"Fowler","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2016.08.004_bib0200","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.8521","article-title":"CALGB 50803 (Alliance): a phase II trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma","author":"Martin","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2016.08.004_bib0205","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1182\/blood.V122.21.248.248","article-title":"Lenalidomide in combination with R-CHOP (R2-CHOP) In patients with high burden follicular lymphoma: phase 2 study","volume":"122","author":"Tilly","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.08.004_bib0210","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1182\/blood-2015-03-633156","article-title":"Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed\/refractory indolent lymphoma","volume":"125","author":"Cheah","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.08.004_bib0215","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1182\/blood.V126.23.471.471","article-title":"Study of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma (Alliance 051103)","volume":"126","author":"Ujjani","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.08.004_bib0220","first-page":"471","article-title":"Advances in the understanding of mechanisms and therapeutic use of bortezomib","volume":"12","author":"Mujtaba","year":"2011","journal-title":"Discov. Med."},{"key":"10.1016\/j.leukres.2016.08.004_bib0225","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.ejca.2012.11.015","article-title":"Efficacy and toxicity of two schedules of bortezomib in patients with recurrent or refractory follicular lymphoma: a randomised phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA)","volume":"49","author":"Ribrag","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.leukres.2016.08.004_bib0230","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1200\/JCO.2008.17.7980","article-title":"Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma","volume":"27","author":"de Vos","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2016.08.004_bib0235","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S1470-2045(11)70150-4","article-title":"Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-na\u00efve or rituximab-sensitive, follicular lymphoma: a randomized phase 3 trial","volume":"12","author":"Coiffier","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2016.08.004_bib0240","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/bjh.12991","article-title":"Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma","volume":"166","author":"Craig","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2016.08.004_bib0245","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1200\/JCO.2010.32.1844","article-title":"Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study","volume":"29","author":"Fowler","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2016.08.004_bib0250","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/bjh.12915","article-title":"Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicenter phase II study","volume":"166","author":"Evens","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2016.08.004_bib0255","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/bjh.13637","article-title":"A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma","volume":"171","author":"Cohen","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2016.08.004_bib0260","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1200\/JCO.2010.33.6594","article-title":"Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group","volume":"29","author":"Sehn","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2016.08.004_bib0265","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1182\/blood.V126.23.1492.1492","article-title":"A phase II trial of Bendamustine, bortezomib, and rituximab in patients with previously untreated low grade lymphoma","volume":"126","author":"Flinn","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.08.004_bib0270","doi-asserted-by":"crossref","first-page":"7507","DOI":"10.1200\/JCO.2016.34.15_suppl.7507","article-title":"Effect of bortezomib on complete remission (CR) rate when added to bendamustine-rituximab (BR) in previously untreated high-risk (HR) follicular lymphoma (FL): a randomized phase II trial of the ECOG-ACRIN Cancer Research Group (E2408)","volume":"34","author":"Evens","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2016.08.004_bib0275","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1182\/blood-2013-11-538546","article-title":"Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-\u03b4, as therapy for previously treated indolent non-Hodgkin lymphoma","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.08.004_bib0280","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2016.08.004_bib0285","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.3109\/10428194.2015.1022770","article-title":"Management of adverse events associated with idelalisib treatment: expert panel opinion","volume":"56","author":"Coutr\u00e9","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2016.08.004_bib0290","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1182\/blood.V124.21.3063.3063","article-title":"Durable responses following treatment with the PI3K-delta inhibitor idelalisib in combination with rituximab, Bendamustine, or both, in recurrent indolent non-Hodgkin lymphoma: phase I\/II results","volume":"124","author":"de Vos","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.08.004_bib0295","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/blood.V124.21.802.802","article-title":"A phase 1 evaluation of duvelisib (IPI-145), a PI3K-\u03b4,\u03b3 inhibitor, in patients with relapsed\/refractory iNHL","volume":"124","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.08.004_bib0300","first-page":"102","article-title":"Long-term follow-up of the next generation PI3K-delta inhibitor TGR-1202 demonstrates safety and high response rates in NHL: integrated-analysis of TGR-1202 monotherapy and combined with ublituximab","volume":"101","author":"O\u2019Connor","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2016.08.004_bib0305","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1182\/blood.V126.23.2706.2706","article-title":"Long-term follow-up and analysis of dose groups with ibrutinib in relapsed follicular lymphoma","volume":"126","author":"Fowler","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.08.004_bib0310","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1182\/blood-2014-08-597914","article-title":"A phase 1\/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed\/refractory non-Hodgkin lymphoma","volume":"125","author":"Maddocks","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.08.004_bib0315","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1182\/blood.V126.23.470.470","article-title":"Ibrutinib plus rituximab in treatment-naive patients with follicular lymphoma: results from a multicenter, phase 2 study","volume":"126","author":"Fowler","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.08.004_bib0320","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2016.08.004_bib0325","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstr\u00f6m's macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2016.08.004_bib0330","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(15)00438-6","article-title":"Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial","volume":"17","author":"Wang","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2016.08.004_bib0335","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1182\/blood-2016-05-712828","article-title":"The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis","volume":"128","author":"Leong","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.08.004_bib0340","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2016.08.004_bib0345","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1182\/blood.V126.23.254.254","article-title":"A phase 1 study of venetoclax (ABT-199\/GDC-0199) monotherapy in patients with relapsed\/refractory non-Hodgkin lymphoma","volume":"126","author":"Gerecitano","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.08.004_bib0350","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/bjh.13487","article-title":"Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies","volume":"170","author":"Roberts","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2016.08.004_bib0355","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease","volume":"30","author":"Roberts","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2016.08.004_bib0360","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2016.08.004_bib0365","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1182\/blood.V126.23.255.255","article-title":"A dose-escalation study of venetoclax (ABT-199\/GDC-0199) in combination with Bendamustine and rituximab in patients with relapsed or refractory non-Hodgkin's lymphoma","volume":"126","author":"de Vos","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.08.004_bib0370","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1182\/blood.V124.21.1716.1716","article-title":"The BCL2 targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 is active in patients with relapsed or refractory non-Hodgkin\u2019s lymphoma","volume":"124","author":"Harb","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.08.004_bib0375","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1182\/blood-2015-02-567453","article-title":"Immune checkpoint blockade in hematologic malignancies","volume":"125","author":"Armand","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.08.004_bib0380","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1470-2045(13)70551-5","article-title":"Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial","volume":"15","author":"Westin","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2016.08.004_bib0385","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase ib study","author":"Lesokhin","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2016.08.004_bib0390","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","article-title":"Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"115","author":"Friedberg","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.08.004_bib0395","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1182\/blood.V126.23.1545.1545","article-title":"Phase 2 trial of entospletinib (GS-9973), a selective syk inhibitor, in indolent non-Hodgkin's lymphoma (iNHL)","volume":"126","author":"Sharman","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.08.004_bib0400","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1182\/blood-2015-12-683516","article-title":"Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL","volume":"127","author":"Barr","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.08.004_bib0405","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1200\/JCO.2010.29.2813","article-title":"Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: the University of Chicago phase II consortium","volume":"28","author":"Smith","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2016.08.004_bib0410","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1002\/cncr.29502","article-title":"A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: a Wisconsin Oncology Network study","volume":"121","author":"Fenske","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2016.08.004_bib0415","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1182\/blood.V126.23.258.258","article-title":"Safety, efficacy, and determination of the recommended phase 2 dose for the oral selective inhibitor of nuclear export (SINE) selinexor (KPT-330)","volume":"126","author":"Chen","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.08.004_bib0420","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1182\/blood.V126.23.574.574","article-title":"Recurrent somatic genomic alterations in follicular NHL (FL) revealed by exome and custom-capture next generation sequencing","volume":"126","author":"Fehniger","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.08.004_bib0425","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2016.08.004_bib0430","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood.V126.23.473.473","article-title":"Phase 1 study of tazemetostat (EPZ-6438), an inhibitor of enhancer of zeste-homolog 2 (EZH2): preliminary safety and activity in relapsed or refractory non-Hodgkin lymphoma (NHL) patients","volume":"26","author":"Ribrag","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.08.004_bib0435","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2016.08.004_bib0440","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.14201","article-title":"The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era","author":"Blaker","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2016.08.004_bib0445","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2016.08.004_bib0450","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2016-05-717355","article-title":"Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy","author":"Jurinovic","year":"2016","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212616301680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212616301680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T16:12:40Z","timestamp":1657037560000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212616301680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":90,"alternative-id":["S0145212616301680"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2016.08.004","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726653982.793557447","asserted-by":"object"}]},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New drugs for follicular lymphoma","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2016.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}